Movatterモバイル変換

[0]ホーム

Jump to content

Technetium (^99mTc) votumumab

Edit links

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

Technetium (^99mTc) votumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	tumor antigen CTAA16.88
Clinical data
ATC code	V09IA04 (WHO)
Legal status
Legal status	not marketed
Identifiers
CAS Number	148189-70-2^N
ChemSpider	none
UNII	63635D7SGF
^NY (what is this?) (verify)

Technetium (^99mTc) votumumab (trade nameHumaSPECT) is a humanmonoclonal antibody labelled with theradionuclide technetium-99m.^[1]^[2] It was developed for the detection ofcolorectal tumors, but has never been marketed.^[3]

The target of votumumab is CTAA16.88, a complex ofcytokeratin polypeptides in the molecular weight range of 35 to 43kDa, which is expressed in colorectal tumors.^[4]

References

[edit]

^"International Nonproprietary Names for Pharmaceutical Substances (INN)"(PDF).WHO Drug Information.13 (1). 1999.
^Hendriks BS, Gaddy DF (2017). "Radiolabeled Antibody-Based Imaging in Clinical Oncology". In Olivier Jr KJ, Hurvitz SA (eds.).Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. Hoboken, New Jersey: John Wiley & Sons. p. 441.ISBN 978-1-119-06084-0.
^"Public Statement on HumaSPECT"(PDF).European Medicines Agency (EMA_. 23 February 2004. Archived fromthe original(PDF) on 2007-06-10.Non-renewal of the marketing authorisation in the European Union
^"Summary of Product Characteristics for HumaSPECT"(PDF).European Medicines Agency (EMA).

Diagnosticradiopharmaceuticals (V09)

Central nervous system

Skeletal system

^99mTc (Medronic acid)

Renal

Gastrointestinal/Hepatic

⁷⁵Se (SeHCAT)

Respiratory system

Cardiovascular system

Inflammation/infection

Tumor

Adrenal cortex

Radionuclides
(includingtracers)

positron (PET list)

gamma ray/photon (SPECT/scintigraphy)

Isotopes used:

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisnuclear medicine article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Technetium_(99mTc)_votumumab&oldid=1166038805"

Categories:

Hidden categories:

[8]ページ先頭